Tumor-infiltrating CD138+ plasma cells are associated with improved prognosis in NSCLC and colorectal cancer 43, 44, but poor prognosis in breast cancer and epithelial ovarian cancer 45, 46. This evidence concerns the gene SDC1 and non-small cell lung carcinoma.